Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Elizabeth Till
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Survivin Selective Inhibitor YM155 Promotes Cisplatin‑induced Apoptosis in Embryonal Rhabdomyosarcoma
International Journal of Oncology
Cancer Research
Oncology
A Phase I and Pharmacokinetic Study of Intraperitoneal Topotecan
British Journal of Cancer
Cancer Research
Oncology
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Phase I and Pharmacokinetic Study of D-Verapamil and Doxorubicin
British Journal of Cancer
Cancer Research
Oncology
Anti-Gd2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Pharmacodynamic and Pharmacokinetic Profile of S 17092, a New Orally Active Prolyl Endopeptidase Inhibitor, in Elderly Healthy Volunteers. A Phase I Study
British Journal of Clinical Pharmacology
Pharmacology
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
